[Oxaliplatin: the first DACH platinum in clinical practice]

Area of Science:

• Oncology
• Pharmacology
• Cancer Research

Background:

• Oxaliplatin is a novel platinum analog with a distinct activity spectrum compared to cisplatin.
• Preclinical studies indicate efficacy against both intrinsic and acquired platinum-resistant cancer cell lines.
• It exhibits additive or synergistic effects when combined with other cytotoxic agents.

Purpose of the Study:

• To evaluate the antitumoral activity and toxicity profile of oxaliplatin.
• To explore its efficacy as a single agent and in combination therapies across various cancer types.
• To assess its potential in platinum-resistant and refractory cancer settings.

Main Methods:

• Preclinical evaluation in platinum-resistant cell lines and in vivo models.
• Phase I, II, and III clinical trials investigating oxaliplatin as a single agent and in combination regimens.
• Assessment of antitumoral response rates and toxicity profiles, including neuropathy, ototoxicity, renal, and myelotoxicity.

Main Results:

• Oxaliplatin demonstrates significant antitumoral activity in colon, ovarian, lung, and other cancers.
• A high response rate (28-65%) was observed in advanced colon cancer using a combination of fluorouracil (FU)/folinic acid/oxaliplatin.
• Significant activity (45% response rate) was noted in resistant/refractory ovarian cancer when combined with cisplatin.
• Sensorial peripheral neuropathy is the primary dose-limiting toxicity, with minimal ototoxicity and renal toxicity.

Conclusions:

• Oxaliplatin is a promising new platinum compound with a unique activity profile and manageable toxicity.
• It shows significant potential as a single agent and in combination therapies for various solid tumors, including platinum-resistant cancers.
• Ongoing and planned clinical trials will further define its role in cancer treatment.